Dr. David Samadi is robotic prostate surgery expert who is also a board certified urologic oncologist. He has spent a good part of his life helping men to catch, diagnose, and treat prostate cancer and is known as one of the best in his industry. He serves Lenox Hill Hospital as its Chief of Robotic Surgery and is also its Chairman of Urology. He has helped more than 7,000 people through successful robotic prostate surgeries and 83% of his patients have regained sexual function. He has been featured on Forbes, Good Morning America, and Fox News Live, and is known to many as the “celebrity doctor” who cares deeply about the patients he serves.
Dr. David Samadi has worked very hard to solve one of the largest problems with prostate cancer, and that is to be able to detect it when it has no symptoms in its early stages. He promotes testing for the disease, because 9 out of 10 patients who catch it early-on will be able to cure it. A simple blood test is enough to discover the early signs of prostate cancer, and Samadi urges men to get tested before they reach the age of 60. He performs close to 15 prostate cancer surgeries every week and has plenty of experience treating the disease through the use of robotic laparoscopic prostate surgery. He strongly believes that this kind of surgery is the future and that it will become more and more advanced over the years.
Dr. David Samadi created the Samadi Modified Advanced Robotic Treatment, also known as SMART, and he has performed over 6,000 prostate cancer surgeries using the system. Close to 9 out of 10 of the recipients of the surgery are now cancer free, and he created SMART to replace open surgery. The Da Vinci surgical system is the most up-to-date, cutting edge tool that helps doctors to avoid the kinds of issues that can occur during prostate cancer surgery. The Da Vinci system makes much smaller incisions and avoids damaging the prostate nerves that so many other surgeries do not. Some of the positive benefits of avoiding damage to these nerves are that men retain their sexual function along with their bladder control.
Dr. David Samadi hopes that new and innovative robotic surgery techniques will become a normal part of medical treatment in the future, and he is certain that his SMART surgery will be among those that are used for quite some time.
Read More: www.huffingtonpost.com/author/dr-david-samadi
Much progress has been made in dealing with cancer, with one of the latest medical techniques using some of the most advanced technology. Tempus, the Chicago-based company established with the help by entrepreneur Eric Lefkofsky, is leading the way in the war on cancer with what is known as data-precision medical treatment.
One of the most important elements in treating cancer is learning how it develops in each person so afflicted, but understanding this issue will require a careful study of the patient’s personal records. This may involve the studying of records that are often in the form of scattered information or notes written by individual doctors. It was Tempus that developed software designed to recognize characters and thus decipher such information in an effective manner.
Another important advancement in cancer research involves the study of health anomalies at the smallest level, specifically in the cells and molecules that comprise the human body. Such studies are today possible through what is known as genome sequencing, or the examination of the genes that are the basis of living organisms. One previous drawback to such research had been its tremendous cost. However, the work of Tempus and other organizations have greatly reduced this expense to manageable levels. The principle of genome sequencing could eventually enable physicians to develop treatment strategies that are customized to individual patients, which can greatly increase the chance of a successful recovery. This philosophy could later be adopted to treat other ailments of health conditions.
Originally from Michigan, 48-year-old Eric Lefkofsky has spent much of his life in and around the Chicago area. A graduate of the University of Michigan, he earned his law degree from the institution in 1993. He is currently serving as an adjunct professor at the University of Chicago’s Booth School of Business.
Lefkofsky has been involved in the creation of several companies, including the e-commerce marketplace Groupon. Inadequacies in the availability of cancer data became a personal matter after his wife was diagnosed with the disease, which spurred the creation of Tempus. The benefits of the work being done by his company could extend to millions of others when considering that, at present rates, approximately 40 percent of American adults will eventually be diagnosed with some type of cancer.
Eric Lefkofsky’s Social Media: www.facebook.com/eplefkofsky/
Clay Siegall Ph.D., the co-founder of Seattle Genetics is a dedicated scientist who is determined to make a difference in the lives of cancer sufferers by discovering new advanced scientific treatments to save the pain of cancer treatment, to save lives and eventually to defeat a disease that has become a scourge to humanity. His expertise was recently sought out by Mirna Therapeutics, a biotechnology company that is focusing on microRNA therapies. This is an area in which Siegall has experience. His position as outside director to its board of directors is a tribute to Siegall’s willingness to sacrifice personal gain for the betterment of humanity.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
These new cancer-fighting technologies specifically attack the cancer cells in the body without ravaging the patient’s valuable blood cells and system defenses.
Siegall is the President of Seattle Genetics as well as its co-founder. His area of expertise was once the domain of Bristol-Myers Squibb Pharmaceutical Research Institute with whom he worked for from 1991 until 1997. Bristol-Myers Squibb decided to stop investigating the area which was Siegall’s expertise, and they moved away from Seattle wanting Siegall to come back East as a valued scientist. He made the decision to stay in Seattle, where he then founded his company to continue with his cancer drug studies.
Siegall is a man dedicated to intense research, innovation, and a passion for helping patients.
His company is at the forefront of developing antibody-drug conjugates and has secured FDA approval of the company’s first product, ADCETRIS (bretuximab vedotin). The drug is now a global brand which has been approved in 60 countries. Siegall has been the recipient of numerous awards, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences, and the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year. He has authored more than 70 publications and developed and maintains 15 patents in his field of study. He received his Ph.D. in Genetics from George Washington University after obtaining his B.S. in Zoology from the University of Maryland.
Siegall is a great addition to Mirna Therapeutics and the world seeking cures for cancer.
Clay Seigall founded Seattle Genteics, Inc. in 1998. For over 18 years Seattle Genetics has been at the forefront of ADC (antibody drug conjugate) clinical trials and innovations. Motivated by his care for people and desire to improve lives Dr. Seigall has placed Seattle Genetics at the forefront of ADC research and clinical trials. Dr. Seigall serves as the President, CEO and Chairman of the board for the company. He obtained a BS in Zoology from the University of Maryland and a Ph.D. in Genetics from George Washington University. Under his leadership Seattle Genetics has raised over 600 million dollars in public and private funds. He is the author of more the seventy poignant publications and owns fifteen patents.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Previously with the National Cancer Institute and Bristol Meyer Squibb Pharmaceutical Research Institute Dr. Seigall has consistently been at the forefront of cancer research. Seattle Genetics has proved to be the premier organization in its field of research. Dr. Seigall and his team have made quite an impact with their first commercial product, Adcetris (brentuximab vedotin)-antibody focused cancer therapy. After receiving fast-tracked approval by the FDA in 2011 for Adcetris, Seattle Genetics continued to see groundbreaking results in ADC developments. The company is currently working on seven additional programs presently in its clinical stage.
Seattle Genetics enjoys its joint ventures with multiple pharmaceutical and biotech companies like Genentech, CuraGen, MedImmune, Progenics and Bayer. Seattle Genetics will certainly continue to offer and provide even more impactful breakthroughs in cancer research for years to come.